喘可治注射液治疗支气管哮喘的系统评价

Meta-Analysis of Chuankezhi Injection in Treating Bronchial Asthma

目的系统评价喘可治注射液治疗哮喘的疗效。方法根据Cochrane系统评价的要求,全面检索万方数据库、CNKI数据库、维普中文科技期刊全文数据库,Pub Med数据库,采用Rev Man5.3软件,对符合纳入标准的23篇文献共1 875例哮喘患者进行Meta分析。结果治疗组与对照组相比,临床有效率[RR=1.13,95%CI(1.08,1.18),P<0.000 01]、第1秒用力呼气容积(FEV1)[MD=0.15,95%CI(0.04,0.27),P<0.000 1]、呼气流量峰值(PEF)[MD=12.74,95%CI(4.01,21.47),P<0.000 1]均明显提高,差异有统计学意义。未报道与喘可治注射液临床应用相关的严重不良反应。结论在常规治疗基础上加用喘可治注射液能有效治疗支气管哮喘,改善肺功能,且安全性较好。

Objective To systematically review the effect of Chuankezhi Injection in the treatment of asthma. Methods According to the requirements of Cochrane system evaluation, databases including PubMed, CNKI, WanFang Data and VIP Chinese PSTP from January 2002 to January 2016 were electronically searched. A total of 23 articles including 1,875 asthma patients were included. Then, meta- analysis was performed using RevMan5.3 software. Results Compared with the control group, the clinical effective rate of the Chuankezhi treatment group was RR = 1.13, 95% CI 1.08 to 1.18, P 〈 0. 000 01. The 1 second forced expiratory volume （FEV1） was MD=0.15,95%CI 0.04 to 0.27, P 〈 0.000 1. Peak expiratory flow （PEF） was MD=12.74,95% CI 4.01 to 21.47, P 〈 0.000 1. All were significantly improved with statistically significant difference. No study reported related serious adverse reactions with the clini- cal application of Chuankezhi Injection. Conclusion Chuankezhi Injection on the basis of conventional treatment can effectively treat bronchial asthma and improve lung function with good safety.